Swiss pharmaceutical giant Roche anti-cancer pipeline has received good news in EU regulation recently. The European Commission (EC) has approved Avastin (common name: bevacizumab, bevacizumab) and Tarceva (General) Name: erlotinib, erlotinib) First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) adult patients with epidermal growth factor receptor (EGFR) activating mutations. The approval also marks the first approval of Avastin's combined monitoring of other targeted therapies.
The European Union approved Avastin in combination with Tarceva for the first-line treatment of EGFR-activated mutant advanced NSCLC, based primarily on data from the critical phase II JO25567 study. The study, a randomized phase II study conducted by Japanese drug company Chugai in Japanese NSCLC patients with EGFR activating mutations, evaluated the efficacy and safety of Avastin+Tarceva combination therapy versus Tarceva monotherapy. Data from 154 patients showed a median progression-free survival (PFS) of 6.3 months in the Avastin+Tarceva combination group compared with the Tarceve monotherapy group (median PFS: 16.0 months vs 9.7 months, HR=0.54, p=0.0015), the risk of disease progression or death decreased significantly by 46%, reaching the primary endpoint of the study.
Signaling pathways targeted by Avastin and Tarceva are key drivers of tumor growth and development. The efficacy of Avastin+Tarceva combination therapy has also been supported by the results of other clinical studies showing that the combination is effective and tolerable.
In Europe and around the world, lung cancer is the leading cause of cancer-related deaths, and NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases.
EGFR is a protein that spans the cell membrane and forms part of the normal cellular signaling pathway. When a specific DNA region of the EGFR gene (exons 19 and 21) is mutated, it triggers structural and functional changes in the EGFR protein, resulting in continuous activation of the EGFR signaling pathway, accelerating cell growth, division, metastasis, and angiogenesis, thereby forming an EGFR activating mutation. Type NSCLC. It is estimated that approximately 10-15% of European NSCLC patients carry EGFR activating mutations, approximately 33,000 per year.
Original source: Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
=========================================================== =========================================================
Related description: Antigen name: EGFR, ErbB, HER1, mENA, ErbB1, PIG61
EGFR is an expression product of the proto-oncogene c-erbB1 and is a member of the epidermal growth factor receptor (HER) family. This family includes HER1 (erbB1, EGFR), HER2 (erbB2, NEU), HER3 (erbB3), and HER4 (erbB4). The HER family plays an important regulatory role in the process of cell physiology. EGFR is widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, etc. EGFR signaling pathway plays an important role in the physiological processes such as cell growth, proliferation and differentiation. Loss of protein tyrosine kinase function such as EGFR or abnormal activity or cell localization of key factors in related signaling pathways can cause tumor, diabetes, immunodeficiency and cardiovascular disease. The EGFR monoclonal antibody blocks the intracellular signal transduction pathway by inhibiting the tyrosine kinase (TK) binding to EGFR, thereby inhibiting the proliferation of cancer cells, inducing apoptosis of cancer cells, and reducing matrix metalloproteinases and blood vessels. Production of endothelial growth factor. Currently available EGFR monoclonal antibody human mouse chimeric IgG1 type monoclonal antibody Cetuximab (cetuximab), fully human IgG2 type monoclonal antibody Panitumumab (panitumumab), humanized IgG1 type monoclonal antibody Nimotuzumab (Netuzumab).
